

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

20 Jun 2026

### Comparison of the effect of preoperative administration of gabapentin and pregabalin on pain control after percutaneous nephrolithotomy

#### Protocol summary

##### Study aim

Determining the effect of pain control from gabapentin and pregabalin after Percutaneous nephrolithotomy

##### Design

Clinical trial with control group, with parallel groups, single-blind, randomized, phase 2, on 66 patients. A random number table will be used for randomization.

##### Settings and conduct

The aim of this study was to determine the effect of pain control from gabapentin and pregabalin after Percutaneous nephrolithotomy. This study is a single blind, randomized clinical trial. The study population is patients undergoing Percutaneous nephrolithotomy. Patients will receive randomly pregabalin capsules 150 mg, gabapentin capsules 300 mg and placebo capsules in 3 intervention groups. The patient will be unaware of the group assigned to him.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria for participants: Patients undergoing percutaneous nephrolithotomy surgery, ASA class I, II, age between 20-60 years, patient informed consent. Exclusion criteria for participants: age under 20 years and over 60 years, history of preoperative renal dysfunction, history of cardiovascular or lung diseases.

##### Intervention groups

Intervention group 1: Patients will receive a 150 mg pregabalin capsule two hours before surgery. Intervention group 2: Patients will receive gabapentin 300 mg capsule two hours before surgery. Control group: Patients will receive placebo capsules two hours before surgery.

##### Main outcome variables

The main outcome of the study: pain.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20200802048275N1**

Registration date: **2021-01-06, 1399/10/17**

Registration timing: **prospective**

Last update: **2021-01-06, 1399/10/17**

Update count: **0**

##### Registration date

2021-01-06, 1399/10/17

##### Registrant information

###### Name

Leila Seyedtabaai

###### Name of organization / entity

###### Country

Iran (Islamic Republic of)

###### Phone

+98 21 7742 0933

###### Email address

leiladrml@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-01-20, 1399/11/01

##### Expected recruitment end date

2021-02-19, 1399/12/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Comparison of the effect of preoperative administration of gabapentin and pregabalin on pain control after percutaneous nephrolithotomy

##### Public title

Effect of gabapentin and pregabalin on pain control after percutaneous nephrolithotomy

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Patient undergoing percutaneous nephrolithotomy Class ASA I, II Age between 20-60 years Patient informed consent

### Exclusion criteria:

Age under 20 years and over 60 years History of preoperative renal dysfunction History of cardiovascular or lung disease

## Age

From **20 years** old to **60 years** old

## Gender

Both

## Phase

2

## Groups that have been masked

- Participant

## Sample size

Target sample size: **66**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Patients receive a random number using the random number table according to their priority entry to the center that matches the numbers on the sealed envelopes. Inside the sealed envelopes is one of the codes A, B and C. A represents the first intervention group that will receive 20 ml of sterile normal saline, B represents the second intervention group that will receive 40 ml of sterile normal saline, and C represents the third intervention group that will receive 60 ml of normal sterile saline. The number of patient in each group is equal.

## Blinding (investigator's opinion)

Double blinded

## Blinding description

Study participants are not aware of their assigned group and will be unaware of the drug used. Of course, they participate in the study with informed consent.

## Placebo

Used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Iran University of Medical

Sciences

#### Street address

Iran University of Medical Sciences, Next to Milad Tower, Hemmat Highway

#### City

Tehran

#### Province

Tehran

#### Postal code

1449614535

#### Approval date

2020-07-19, 1399/04/29

#### Ethics committee reference number

IR.IUMS.FMD.REC.1399.277

## Health conditions studied

### 1

#### Description of health condition studied

Percutaneous nephrolithotomy

#### ICD-10 code

N20.0

#### ICD-10 code description

Calculus of kidney

## Primary outcomes

### 1

#### Description

Pain

#### Timepoint

Before surgery, recovery, 4, 6 and 12 hours after surgery

#### Method of measurement

Visual Analogue Scale (VAS)

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: wo hours before surgery, a 150 mg pregabalin capsule is given.

#### Category

Treatment - Drugs

### 2

#### Description

Intervention group: two hours before surgery, a 300 mg gabapentin capsule is given.

#### Category

Treatment - Drugs

### 3

#### Description

Control group: two hours before surgery, a placebo capsule is given.

**Category**

Treatment - Drugs

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Hasheminejad Hospital

**Full name of responsible person**

Masoud Ghorbanloo

**Street address**

Shahid Valinejad Alley, Above Vanak Square, Vali Asr St

**City**

Tehran

**Province**

Tehran

**Postal code**

1969714713

**Phone**

+98 21 81161

**Email**

support@hkc.ir

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Iran University of Medical Sciences

**Full name of responsible person**

Seyed Abbas Motevalian

**Street address**

Iran University of Medical Sciences, Next to Milad Tower, Hemmat Highway

**City**

Tehran

**Province**

Tehran

**Postal code**

1449614535

**Phone**

+98 21 8670 2504

**Fax**

**Email**

research-m@iums.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Iran University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Iran University of Medical Sciences

**Full name of responsible person**

Masoud Ghorbanloo

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Hashemi nezhad Hospital, Shahid Valinejad Alley, Above Vanak Square, Vali Asr St

**City**

Tehran

**Province**

Tehran

**Postal code**

1969714713

**Phone**

+98 21 81161

**Email**

masoudghorbanlo@yahoo.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Iran University of Medical Sciences

**Full name of responsible person**

Masoud Ghorbanloo

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Hashemi nezhad Hospital, Shahid Valinejad Alley, Above Vanak Square, Vali Asr St

**City**

Tehran

**Province**

Tehran

**Postal code**

1969714713

**Phone**

+98 21 81161

**Email**

masoudghorbanlo@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Iran University of Medical Sciences

**Full name of responsible person**

Leila Sadat Seyed Tabaei

**Position**

Rezident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Anesthesiology

**Street address**

Shahid Valinejad Alley, Above Vanak Square, Vali Asr  
St

**City**

Tehran

**Province**

Tehran

**Postal code**

1969714713

**Phone**

+98 21 81161

**Fax****Email**

leiladrml@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available

**Title and more details about the data/document**

All potential data is shared after unidentifiable people.

**When the data will become available and for how long**

Start of access period 6 months after printing results

**To whom data/document is available**

Researchers working in academic and scientific institutions

**Under which criteria data/document could be used**

There are no special conditions.

**From where data/document is obtainable**

Dr. Massoud Ghorbanloo

**What processes are involved for a request to access data/document**

After reviewing the applicant's request, it will be sent to him.

**Comments**